Literature DB >> 27533122

Bortezomib Treatment for Patients With Anti-N-Methyl-d-Aspartate Receptor Encephalitis.

Volker Behrendt1, Christos Krogias1, Anke Reinacher-Schick2, Ralf Gold1, Ingo Kleiter1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27533122     DOI： 10.1001/jamaneurol.2016.2588

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN： 2168-6149            Impact factor:   18.302


× No keyword cloud information.
  19 in total

1.  The short-term efficacy of combined treatments targeting B cell and plasma cell in severe and refractory Anti-N-methyl-D-aspartate receptor encephalitis: Two case reports.

Authors:  Xiao-Ting Zhang; Chun-Juan Wang; Bao-Jie Wang; Shou-Gang Guo
Journal:  CNS Neurosci Ther       Date:  2018-10-21       Impact factor: 5.243

Review 2.  ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).

Authors:  G Redelman-Sidi; O Michielin; C Cervera; C Ribi; J M Aguado; M Fernández-Ruiz; O Manuel
Journal:  Clin Microbiol Infect       Date:  2018-02-07       Impact factor: 8.067

3.  Severe refractory CIDP: a case series of 10 patients treated with bortezomib.

Authors:  Kalliopi Pitarokoili; Min-Suk Yoon; Ilka Kröger; Anke Reinacher-Schick; Ralf Gold; Christiane Schneider-Gold
Journal:  J Neurol       Date:  2017-08-23       Impact factor: 4.849

Review 4.  [Update on anti-N-methyl-D-aspartate receptor encephalitis].

Authors:  S Kovac; J Alferink; D Ahmetspahic; V Arolt; N Melzer
Journal:  Nervenarzt       Date:  2018-01       Impact factor: 1.214

Review 5.  Refractory anti-NMDAR encephalitis successfully treated with bortezomib and associated movements disorders controlled with tramadol: a case report with literature review.

Authors:  Marco Vabanesi; Serena Marita Lazzarin; Giordano Cecchetti; Raffaella Fazio; Giovanna Franca Fanelli; Maria Antonietta Volonté; Angela Genchi; Antonino Giordano; Vittorio Martinelli; Sergio Colombo; Paolo Beccaria; Milena Mucci; Jacopo Peccatori; Massimo Filippi; Fabio Minicucci
Journal:  J Neurol       Date:  2020-06-13       Impact factor: 4.849

Review 6.  B-cell-targeted therapies in relapsing forms of MS.

Authors:  Divyanshu Dubey; Thomas Forsthuber; Eoin P Flanagan; Sean J Pittock; Olaf Stüve
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-10-23

7.  Management of Autoimmune Encephalitis: An Observational Monocentric Study of 38 Patients.

Authors:  Stefan Macher; Friedrich Zimprich; Desiree De Simoni; Romana Höftberger; Paulus S Rommer
Journal:  Front Immunol       Date:  2018-11-22       Impact factor: 7.561

Review 8.  Treatment strategies for autoimmune encephalitis.

Authors:  Yong-Won Shin; Soon-Tae Lee; Kyung-Il Park; Keun-Hwa Jung; Ki-Young Jung; Sang Kun Lee; Kon Chu
Journal:  Ther Adv Neurol Disord       Date:  2017-08-16       Impact factor: 6.570

9.  Bortezomib treatment for severe refractory anti-NMDA receptor encephalitis.

Authors:  Yong-Won Shin; Soon-Tae Lee; Tae-Joon Kim; Jin-Sun Jun; Kon Chu
Journal:  Ann Clin Transl Neurol       Date:  2018-03-23       Impact factor: 4.511

10.  International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis.

Authors:  Margherita Nosadini; Terrence Thomas; Michael Eyre; Banu Anlar; Thais Armangue; Susanne M Benseler; Tania Cellucci; Kumaran Deiva; William Gallentine; Grace Gombolay; Mark P Gorman; Yael Hacohen; Yuwu Jiang; Byung Chan Lim; Eyal Muscal; Alvin Ndondo; Rinze Neuteboom; Kevin Rostásy; Hiroshi Sakuma; Suvasini Sharma; Silvia Noemi Tenembaum; Heather Ann Van Mater; Elizabeth Wells; Ronny Wickstrom; Anusha K Yeshokumar; Sarosh R Irani; Josep Dalmau; Ming Lim; Russell C Dale
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.